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Background
Recent studies have identified a high prevalence of the MYD88 L265P mutation in lympho-
plasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM) cases, whereas 
low frequencies have been observed in other B cell non-Hodgkin lymphomas (NHLs). 
Methods
We evaluated the sensitivity of the mutant enrichment 3’-modified oligonucleotide 
(MEMO)-PCR technique, a new detection method. We examined the MYD88 L265P mu-
tation in a series of Korean patients with LPL/WM and other B cell NHLs in bone marrow 
aspirates, using the MEMO-PCR technique. 
Results
The sensitivity of MEMO-PCR was estimated to be approximately 10‒16.7%. MYD88
L265P was detected in 21 of 28 LPL cases (75%) and only three of 69 B cell NHL cases 
(4.3%). 
Conclusion
Although MEMO-PCR had relatively low sensitivity, we confirmed the high prevalence 
of the MYD88 L265P mutation in Korean LPL patients. Our study suggests the diagnostic 
value of MYD88 L265P for differentiating B-cell NHLs.
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INTRODUCTION
Lymphoplasmacytic lymphoma/Waldenstrom macro-
globulinemia (LPL/WM) is a relatively rare subgroup of 
non-Hodgkin lymphoma (NHL). Differential diagnosis of 
LPL/WM from other NHLs is somewhat difficult, especially 
from marginal zone lymphoma (MZL) or B cell lymphoma 
with plasmacytic differentiation [1, 2]. Recent studies have 
reported a high prevalence (80-100%) of the MYD88 L265P 
mutation in LPL/WM compared to a low prevalence in other 
NHLs; therefore, testing for this mutation could be of diag-
nostic value [3-5]. The incidence of LPL in Korea has been 
suggested to be low (0.8%) compared to that in western 
countries [6]. One recent study on Korean patients with 
LPL/WM also showed a relatively high prevalence (69%) 
of MYD88 L265P [7], whereas studies on other NHLs showed 
a low prevalence [8, 9]. 
The detection methods for MYD88 L265P differed among 
different studies, and included conventional Sanger sequenc-
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Fig. 1. Principles of MEMO-PCR for 
MYD88 L265P detection. Blocking 
primers, complementary to the 
normal sequence, anneal to normal 
DNA, hampering PCR amplifica-
tion. In the presence of a missense 
mutation, the binding affinity of the 
blocking primers to the mutant 
DNA is decreased due to the mis-
match, and therefore, amplifica-
tion of the mutant DNA is markedly 
enhanced.
ing, allele-specific PCR (AS-PCR), and real-time PCR assays 
[4, 10]. The specimens for molecular testing can be obtained 
from the lymph node, bone marrow aspirate, or peripheral 
blood samples. Since there is a high chance of inclusion 
of stromal and normal hematopoietic cells in such specimens, 
more sensitive methods will be required for accurate testing. 
In this study, we investigated the MYD88 L265P prevalence 
in Korean patients with LPL/WM and other B-cell NHLs 
using mutant enrichment 3ˊ-modified oligonucleotide 
(MEMO)-PCR and sequencing, a sensitive technique with 
low false-positive rates [11-13]. We observed a relatively 
high frequency of MYD88 L265P and determined the clinical 
utility of testing for this mutation. 
MATERIALS AND METHODS
Patients and specimens
From a review of LPL/WL and other B-cell NHL cases 
diagnosed at the Samsung Medical Center between 2001 
and 2014, we selected 97 cases with bone marrow involve-
ment, including 28 LPL/WL and 69 other B-cell NHL cases. 
Patient demographics, clinical features, treatment histories, 
and hematologic, immunophenotypic, and cytogenetic find-
ings were all comprehensively analyzed. To identify the 
deletion of 6q, we additionally performed fluorescence in 
situ hybridization (FISH) using the XL 6q21/6q23 probe 
(Metasystem, Altlussheim, Germany). For the evaluation of 
MEMO-PCR, samples were diluted with equimolar normal 
DNA to produce 1:1, 1:3, 1:5, 1:9, 1:17, 1:21, and 1:41 ratios 
of mutant DNA.
Mutant enrichment 3ˊ-modified oligonucleotide–PCR 
(MEMO-PCR) and sequencing
DNA was extracted from bone marrow aspirate slides using 
the QIAamp DNA Blood Mini Kit (Qiagen, Foster City, CA, 
USA) after treating with proteinase K. To detect the MYD88 
L265P by MEMO-PCR, we designed generic forward (5ˊ- 
CAGGTGCCCATCAGAAGC-3ˊ) and reverse (5ˊ-GAAGTTG 
GCATCTCCAGGAA-3ˊ) primers along with a blocking pri-
mer (5ˊ-AAGCGACTGATCCCCATCAA-[C3 spacer]-3ˊ) em-
ploying a C3 spacer at the 3ˊ end. PCR amplification was 
performed using these three primers (10, 10, and 50 pmol 
each, respectively), with the following amplification cycle: 
94oC for 5 min, 40 cycles of the main reaction (94oC for 
30 s, 59oC for 30 s, and 72oC for 60 s), and 72oC for 7 
min. Downstream sequencing analysis was performed using 
the BigDye Terminator Cycle Sequencing Ready Reaction 
Kit on the ABI Prism 3130 Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA). Principles of MEMO-PCR 
for MYD88 L265P detection are shown in Fig. 1 [12].
Statistical analysis
Statistical analysis was performed using PASW Statistics 
20.0 software (IBM, Armonk, New York, USA). To compare 
the clinical parameters between MYD88 L265P positive and 
negative groups, we performed a chi-square test for catego-
rical variables and a Mann-Whitney test or student’s t-test 
for continuous variables. A P-value＜0.05 was considered 
statistically significant.
RESULTS
Clinical characteristics of LPL/WM
Patient demographics and clinical characteristics of cases 
are summarized in Table 1. The mean age was 65 years 
and the male/female ratio was 1.8:1. Patients generally had 
mild anemia (mean 9.7 g/dL) with variable white blood cell 
and platelet counts. All patients had IgM-type monoclonal 
gammopathies, except for one patient with IgG-type. 
Chromosomal aberration was detected in three of 25 patients 
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Fig. 2. Sensitivity of MEMO-PCR (estimated to be approximately 10–16.7%) and sequencing analysis.
Table 1. Demographics and clinical characteristics of LPL/WM.
LPL/WM 
(N=28)
Other NHL 
(N=69)
Age, years (mean±SD) 65±13.0 56±15.9
Male/female 18/10 54/15
Treated/untreated (initial diagnosis) 1/27 8/61
Hemoglobin, g/dL (mean±SD) 9.7±2.3 11.8±2.0
White blood cell, ×109/L (mean±SD) 5.9±2.2 14.9±15.7
Platelet, ×109/L (mean±SD) 220±102 158±83
BUN (mean±SD) 17.2±5.8 16.8±12.2
Serum creatinine (mean±SD) 1.3± 1.2 1.1±1.9
Lymphoma cell, % (mean±SD) 50.6±23.0 46.2±29.5
Monoclonal gammopathy 28 11
IgG/IgA/IgM/not available 1/0/27/0 0/0/5/6
6q deletion, confirmed by FISH 5/13 (38.5%) NA
Chromosome aberration 3/25 (12%) 36 (52.2%)
Abbreviations: FISH, fluorescence in situ hybridization; BUN, 
blood urea nitrogen; LPL/WM, lymphoplasmacytic lymphoma/ 
Waldenstrom macroglobulinemia; NA, not available; NHL, 
non-Hodgkin lymphoma; SD, standard deviation.
analyzed (12%), including two complex karyotypes and one 
single balanced translocation. By FISH analysis, a 6q deletion 
was detected in 38.5% (5/13) of LPL/WM cases, suggesting 
that the deletion is cryptic. One case was CD5-positive (1/19, 
5.3%). The positivity rate of CD23, CD25, and FMC-7 was 
29.4% (5/17), 22.2% (2/9), and 50% (9/18), respectively.
Clinical characteristics of NHL
Demographic and clinical characteristics of the enrolled 
patients are summarized in Table 1. The mean age was 56 
years and male/female ratio was 3.6:1. Patients generally 
had mild anemia (mean 11.8 g/dL) with variable white blood 
cell and platelet counts. Eleven patients had monoclonal 
gammopathies, which were most commonly of the IgM-type. 
Chromosome aberration was detected in 36 patients (52.2%).
Detection of MYD88 L265P
Using diluted samples, the sensitivity of MEMO-PCR was 
estimated to be approximately 10–16.7% (Fig. 2). By MEMO- 
PCR and sequencing of bone marrow aspirate specimens, 
MYD88 L265P was detected in 21 (75%) of 28 LPL/WM 
cases. In other B-cell NHLs, this mutation was detected in 
only three cases (4.3%), including B-cell prolymphocytic 
leukemia, marginal zone lymphoma, and follicular lympho-
ma (Table 2). 
None of the clinical and cytogenetic parameters were sig-
nificantly different between MYD88 L265P positive and neg-
ative groups (Table 3). Nonetheless, we observed relatively 
high serum paraprotein levels in the mutation-positive group 
compared to the wild type group (3.10±1.57 g/dL vs. 
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Table 2. Prevalence of MYD88 L265P in LPL/WM and other B-cell NHLs.
MYD88 L265P
N of positive/total patients
B-cell prolymphocytic leukemia 1/1
Marginal zone lymphoma 1/8
Follicular lymphoma 1/13
Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia 21/28
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma 0/2
IgM-type myeloma 0/2
Burkitt lymphoma 0/9
Diffuse large B-cell lymphoma 0/11
Mantle cell lymphoma 0/11
Chronic lymphocytic leukemia/small lymphocytic lymphoma 0/12
Table 3. Clinical characteristics of LPL/WM according to MYD88 L265P status.
LPL/WM (N=28)
L265P –positive (N=21, 75%) L265P –negative (N=7, 25%) P
Age, years (mean±SD) 66.9±19.9 60.3±19.9 0.499
Male/female 15/6 3/4 0.207
Hemoglobin, g/dL (mean±SD) 9.5±2.4 10.3±2.2 0.405
Whit blood cell, ×109/L (mean±SD) 6.2±2.3 5.1±1.7 0.228
Platelet, ×109/L (mean±SD) 228.2±114.6 195.0±48.5 0.405
BUN (mean±SD) 17.3±6.1 16.9±4.9 0.882
Serum creatinine (mean±SD) 1.12±0.29 1.85±2.55 0.355
Lymphoma cell % (mean±SD) 51.5±24.5 48.3±19.8 0.790
M-peaka), g/dL (mean±SD) 3.10±1.57 1.76±1.06 0.119
6q deletion 1/3 (33.3%) 4/10 (40%) 1.000
Lymphadenopathy 13/21 (61.9%) 3/7 (42.9%) 0.418
Hepatosplenomegaly 17/21 (81.0%) 3/7 (42.9%) 0.142
a)17 cases and 6 cases were available for serum paraprotein levels.
Abbreviations: BUN, blood urea nitrogen; LPL/WM, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia; SD, standard deviation.
1.76±1.06 g/dL, respectively; P=0.119).
DISCUSSION
We observed a high prevalence of the MYD88 L265P 
mutation in Korean LPL/WM patients, which was similar 
to results of previous studies [7, 10, 14]. In 2012, Treon 
et al. initially described a high prevalence of MYD88 L265P 
in LPL/WM (91%) using whole genome sequencing [14]. 
They also developed real-time AS-PCR assays for sensitive 
detection and quantification of MYD88 L265P [10]. Other 
subsequent studies confirmed this high prevalence (over 
90%) in LPL/WM and in IgM monoclonal gammopathy of 
undetermined significance (MGUS; up to 87% of cases) [5, 
15]. In addition, MYD88 L265P was considered a risk factor 
for progression to LPL/WM or other lymphomas in patients 
with IgM MGUS [15-17].
MYD88 L265P can be detected in other B-cell NHLs; 
for example, approximately 30% of cases of the activated 
B-cell-like (ABC) subtype of diffuse large B-cell lymphoma 
(DLBCL) had the MYD88 L265P mutation [18]. Bonzheim 
et al. [19] have reported a high prevalence of MYD88 L265P 
(69%) in vitreoretinal diffuse large B-cell lymphomas. Cases 
of splenic marginal zone lymphomas and chronic lympho-
cytic lymphomas have also been reported to have MYD88 
L265P although the frequencies are relatively low (10% and 
4%, respectively) [10]. We also observed MYD88 L265P in 
three case of B-cell NHL, including B prolymphocytic leuke-
mia, marginal zone lymphoma, and follicular lymphoma. 
These observations indicate that MYD88 L265P should not 
be considered an exclusive diagnostic marker of WM/LPL. 
Nonetheless, MYD88 L265P is relatively rare in marginal 
zone lymphomas, IgM myelomas, or chronic lymphocytic leu-
kemia, of which the discrimination from LPL/WM is difficult. 
Therefore, the diagnostic utility of MYD88 L265P testing for 
differential diagnosis will be still valuable [1, 5, 15].
Several studies have shown the association of the MYD88 
L265 mutation with higher bone marrow tumor burden [3, 
10, 20, 21], serum paraprotein levels [15, 20], and probability 
bloodresearch.or.kr Blood Res 2016;51:181-6.
MYD88 L265P in LPL/WM 185
of progression [15, 16, 20]. In contrast, we could not identify 
any significant differences in laboratory and clinical parame-
ters between MYD88 L265P positive and negative cases. 
This might be because of the small number of cases enrolled 
and the heterogeneity of clinical and pathological charac-
teristics. Regarding cytogenetic abnormalities, no karyotype 
is known to be specific to LPL/WM. Loss of 13q14, 11q21-q22, 
and 6q23–q24 and gain of 3, 12, and 18 are reported to 
be common in LPL/WM [22] but these abnormalities are 
also common in other low-grade lymphomas such as MZL 
and CLL [22, 23]. We observed only three LPL/WM cases 
with chromosomal abnormalities by conventional chromo-
some analysis; however, a high frequency of 6q deletion 
(38.5%) was detected with FISH, which is in accordance 
with another study on Korean LPL/WM patients [7]. This 
report described an association between 6q deletion and 
MYD88 L265P mutation [7]. However, we failed to find 
a similar association; cases with a 6q deletion also had a 
high frequency of MYD88 L265P mutation.
For molecular testing, we used bone marrow aspirate slides 
instead of biopsy specimens from primary sites such as lymph 
nodes. Given that the detection method is sensitive, obtaining 
samples from bone marrow or peripheral blood specimens 
will be more practical and easier than performing biopsies 
on primary sites. One popular method for this purpose is 
AS-PCR, used in many studies for MYD88 L265P detection 
[4, 10, 16, 24, 25]. AS-PCR shows good sensitivity but some-
times suffers the drawback of high false-positive rates [13, 
26]; therefore, we adopted a MEMO-PCR method with high 
specificity [11, 13, 27] and confirmed that this technique 
could be efficiently used for the detection of MYD88 L265P 
mutations in LPL/WM and other B-cell NHLs.
Several limitations were encountered in this study. We 
did not perform extensive clinical and morphologic review 
of selected cases to differentiate LPL/WM from other lym-
phoma diagnoses. In addition, only a few cases of MZL or 
B cell lymphoma with plasmatic differentiation were en-
rolled in this study. The sensitivity of MEMO-PCR was in-
sufficient to detect minimal mutant levels of MYD88 L265P. 
This low sensitivity could have caused the relatively low 
mutation prevalence (75%), when this parameter was com-
pared to that in other studies (∼90%). Therefore, clinical 
and laboratory differences, according to mutation status, 
might not have yielded statistical significance in this study. 
Further optimization of MEMO-PCR and sequencing might 
be required to increase detection sensitivity.
In conclusion, we observed a high prevalence of MYD88 
L265P in LPL/WM and a low prevalence in other NHLs 
based on a series of Korean patients. Although several limi-
tations were encountered in this study, our results demon-
strate the diagnostic value of MYD88 L265P for differ-
entiating B-cell NHLs. 
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